Providence Genomics and EACRI researchers conducted a multi-year study of the impact of removing testing barriers to comprehensive genomic profiling (CGP) for patients with advanced cancers.
The study’s motivation stemmed from inadequacies in the delivery of consistent, timely, and comprehensive genomic testing for cancer patients.
The team’s findings showed that patients in the study who received CGP-guided precision therapy had significantly higher survival outcomes.
